Bipartisan bill on follow-on biologics unveiled in Congress

03/11/2009 | Reuters · Google

Reps. Henry Waxman, D-Calif., and Nathan Deal, R-Ga., on Wednesday introduced a proposal that would allow the FDA to approve follow-on biologics. The bill would give brand-name biotech drugs three to five years of market exclusivity, shorter than the 14 years requested by biotech companies. The legislation would lead to a path that "jeopardizes the continued development of new breakthrough therapies and potential cures for debilitating diseases," BIO President Jim Greenwood said.

View Full Article in:

Reuters · Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN